Condition
Diffuse Lewy Body Disease
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02702102Phase 2CompletedPrimary
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
NCT02761707Completed
Biomarkers in Neural Disorders
NCT02281474Phase 1Completed
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
NCT00465790Completed
Research of Biomarkers in Parkinson Disease
Showing all 4 trials